Diagnostics

With €7.5M from Europe’s top innovation fund, a Belgian startup is not just correcting vision—it’s turning the eye into a window for our overall health.

A breakthrough melanoma test from SkylineDx has earned rare dual recognition, promising to reshape patient care by reducing unnecessary surgeries.

With a proven test but lagging sales, Sera Prognostics taps a diagnostics veteran to navigate the treacherous path from clinical validation to market success.

A new survey reveals a staggering disconnect: midlife women are ready for early Alzheimer's testing, but the healthcare system is failing to start the conversation.

A new report shows a five-year low in student drug positivity rates, yet a deeper analysis reveals a complex landscape of risk shaped by fentanyl and synthetics.

Trinity Biotech, a diagnostics firm, is entering the $27B AI cooling market. Can its expertise in high-purity fluids solve the data center thermal crisis?

The Association for Diagnostics & Laboratory Medicine's new leadership, led by Dr. Christina Lockwood, signals a decisive move to tackle healthcare's biggest challenges.

Exact Imaging's U.S. expansion signals a major shift. With technology rivaling MRI, micro-ultrasound is poised to make precision diagnostics more accessible.

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.

As new treatments for degenerative eye disease emerge, OpZira's hiring of a key innovator from its past signals a major push into AI-driven diagnostics.

With stringent NYS approval secured, Fellow Health’s mail-in semen analysis enters a key market, signaling a major shift in at-home diagnostics and male reproductive care.

Landmark 2-year study shows an AI diagnostic for diabetic kidney disease actively improves patient outcomes, validating a new era of precision medicine.

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.

GuideAI Health's new AI platform just hit the public market. It promises to find hidden vascular disease in routine scans, but can it navigate the risks?

A new blood test and a powerful partnership between a diagnostics firm and a patient foundation aim to end years of misdiagnosis for a rare lung disease.

A new partnership brings advanced, FDA-cleared HPV testing to the home. The true innovation, however, is the system built to overcome the last-mile problem.

Co-Dx's local-first strategy empowers communities against disease, but can this innovative public health play overcome the company's financial headwinds?

As Abbott prepares its July 16th earnings report, all eyes are on more than just the balance sheet. It's a test of its post-acquisition strategy.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.